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Background: The aim of this study was to compare the 5-year clinical outcomes of sirolimus-eluting stents (SES) in the ARTS (Arterial 
Revascularization Therapies Study)-II with the outcomes of coronary artery bypass graft (CABG) and bare metal stenting (BMS) from the ARTS-I study, 
in patients who had multivessel coronary artery disease with and without diabetes mellitus.
Methods: The ARTS-II trial is a single-arm study (n = 607) that included 159 diabetics treated with SES. The 5-year clinical results were compared 
with the historical cohorts of the randomized ARTS-I (n = 1,205, including 96 diabetics in the CABG arm and 112 in the PCI arm).
Results: At 5 years, among diabetics, the composite of death, Cerebrovascular Accident (CVA) or Myocardial Infarction (MI) was lower in ARTS II SES 
(15.1%) than ARTS-I BMS (25.0%, logrank p=0.03) and similar to ARTS-I CABG (16.7%, logrank p=0.65). The composite of major adverse cardiac 
and cerebrovascular events (MACCE: death, CVA, MI or repeat revascularization) was 39.6 % in SES, which was higher than CABG (22.9%, logrank 
p=0.01) but lower than BMS (53.6%, logrank p=0.005).
In nondiabetics, the composite of death, CVA or MI was lower in SES (11.8%) than in BMS (16.2%, logrank p=0.04) and similar to CABG (13.3%, 
logrank p=0.38). The MACCE rate was 22.8 % in SES, which was comparable with CABG (20.5%, logrank p=0.57) but lower than BMS (38.3%, logrank 
p<0.001)
Conclusions: PCI with SES might be a variable alternative to CABG in non-diabetic patients with multivessel disease.
